ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Renal"

  • Abstract Number: 1566 • ACR Convergence 2024

    Comparative Analysis of Clinical Features and Outcomes in Late Onset vs. Early Onset Scleroderma Renal Crisis – A Multicenter Study

    Sumbal Wajid1, Lee Shapiro2, Virginia Steen3, Robyn Domsic4, Paul J. Feustel5 and Swati Mehta6, 1Albany Medical Center, Albany, NY, 2Division of Rheumatology, Department of Medicine, Albany Medical Center, Albany, NY, 3Georgetown University School of Medicine, Washington, DC, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 5Department of Neuroscience and Experimental Therapeutics, Albany Medical Center, Albany, NY, 6Division of Nephrology, Department of Medicine, Albany Medical Center, Albany, NY

    Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication of systemic sclerosis (SSc), historically described to occur within the first 5 years of SSc diagnosis.…
  • Abstract Number: 0659 • ACR Convergence 2024

    Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial

    Richard Furie1, Jorge A. Ross Terres2, Elsa Martins3, Imran Hassan4, Thomas Schindler3, Jay Garg5, William F. Pendergraft III6, Ana Malvar7 and Brad Rovin8, 1Northwell Health, Manhasset, NY, 2Genentech, Inc,, San Francisco, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc., South San Francisco, CA, 6Genentech, Inc., Chapel Hill, NC, 7Organización Médica de Investigación, Buenos Aires, Argentina, 8The Ohio State University, Columbus, OH

    Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
  • Abstract Number: 1569 • ACR Convergence 2024

    Scleroderma Renal Crisis – Different Phenotypes and Patient Trajectories

    Katya Dolnikov1, Kochava Toledano1, Marius Braun2, Doron Markovits1, Sami Giryes1, Yonit Tavor1, Alexandra Balbir-Gurman3 and Yolanda Braun Moscovici1, 1Rheumatology Institute, Rambam Health Care Campus, Rappaport Faculty of Medicine, Technion-Israeli Institute of Technology, HAIFA, Israel, 2Liver Insitute, Beilinson Hospital, Petach Tikva, Petach Tikva, Israel, 3Rheumatology Institute, Rambam Health Care Campus and The Rappaport Faculty of |Medicine, Technion, Haifa, Israel

    Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening complication that occurs in a minority of patients, particularly those with diffuse cutaneous systemic sclerosis ( SSc).…
  • Abstract Number: 0621 • ACR Convergence 2023

    Scleroderma Renal Crisis: A Large Single-center Experience

    Rushab Shah1, laura ross2, Kathleen Morrisroe3, Wendy Stevens4 and Mandana Nikpour5, 1St Vincent's Hospital Melbourne/ Alfred Hospital, Melbourne, Australia, 2St. Vincent's Hospital Melbourne, Fitzroy, Australia, 3The University of Melbourne at St Vincent’s Hospital Melbourne, Fitzroy, Australia, 4Department of Rheumatology, St Vincent's Hospital Melbourne, Fitzroy, Australia, 5The University of Melbourne at St. Vincent’s Hospital Melbourne, Departments of Medicine and Rheumatology, Melbourne, Australia

    Background/Purpose: Scleroderma renal crisis (SRC) is a life-threatening vascular manifestation of systemic sclerosis (SSc) occurring in up to 5% of SSc patients. This condition continues…
  • Abstract Number: 1541 • ACR Convergence 2023

    Neurologic Involvement Does Not Affect Cumulative Survival Rates in Patients with ANCA-associated Vasculitis and Is Less Commonly Associated with Rapidly Progressive Glomerulonephritis in Patients with GPA

    Gatr-alnada Gheriani1 and Petar Lenert2, 1University of Iowa Hospital and Clinics, Tiffin, IA, 2University of Iowa Hospitals and Clinics, Iowa City, IA

    Background/Purpose: The aim of this study was to analyze the incidence of nervous system manifestations in a cohort of patients with Microscopic Polyangiitis (MPA) and…
  • Abstract Number: 0683 • ACR Convergence 2023

    Remission, Glucocorticoid Toxicity, Health-Related Quality of Life, and Safety Outcomes in Patients with Renal Involvement in the Phase 3 Trial of Avacopan for the Treatment of ANCA-Associated Vasculitis

    Duvuru Geetha1, Frank Cortazar2, Annette Bruchfeld3, alexandre Karras4, Peter Merkel5 and David Jayne6, 1Johns Hopkins University, Baltimore, MD, 2New York Nephrology, Watervliet, NY, 3Karolinska Institutet, Stockholm, Sweden, 4HEGP - APHP, Paris, France, 5University of Pennsylvania, Philadelphia, PA, 6University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: In the Phase 3 ADVOCATE trial comparing avacopan to a prednisone taper, 81% of patients with ANCA-associated vasculitis (AAV) had renal involvement based on…
  • Abstract Number: 1695 • ACR Convergence 2023

    Single Cell Transcriptomics in Kidney Tissue from African American Patients Enrolled in the Accelerating Medicines Partnership (AMP) Implicates Tubular Cells in the Pathogenesis of APOL1 Associated Lupus Nephritis

    Philip Carlucci1, Jasmine Shwetar2, Siddarth Gurajala3, Qian Xiao3, Joseph Mears4, Katie Preisinger1, Devyn Zaminski5, Kristina Deonaraine1, Peter Izmirly1, Andrea Fava6, Judith James7, Joel Guthridge7, Brad Rovin8, Sethu Madhavan8, Wade DeJager7, David Wofsy9, Ming Wu2, Chaim Putterman10, Deepak Rao11, Betty Diamond12, Derek Fine13, Jose Monroy-Trujillo13, Kristin Haag14, H Michael Belmont5, William Apruzzese11, Anne Davidson12, Fernanda Payan-Schober15, Richard Furie16, Paul Hoover11, Celine Berthier17, Maria Dall'Era9, Kerry Cho18, Diane L. Kamen19, Kenneth Kalunian20, Jennifer Anolik21, Arnon Arazi22, Soumya Raychaudhuri11, Nir Hacohen23, Michelle Petri24, Robert Clancy25, Kelly Ruggles2, Jill Buyon25 and The Accelerating Medicines Partnership in RA/SLE26, 1New York University School of Medicine, New York, NY, 2NYU Langone, New York, NY, 3Harvard Medical School, Boston, MA, 4Michigan University, Ann Arbor, MI, 5NYU School of Medicine, New York, NY, 6Johns Hopkins University, Baltimore, MD, 7Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Ohio State University, Columbus, OH, 9University of California San Francisco, San Francisco, CA, 10Albert Einstein College of Medicine, Bronx, NY, 11Brigham and Women's Hospital, Boston, MA, 12Feinstein Institutes for Medical Research, Manhasset, NY, 13Johns Hopkins School of Medicine, Baltimore, MD, 14Thomas Jefferson University, Philadelphia, PA, 15Texas Tech University Health Sciences Center, El Paso, TX, 16Northwell Health, Manhasset, NY, 17University of Michigan, Ann Arbor, MI, 18UCSF Health, San Francisco, CA, 19Medical University of South Carolina, Charleston, SC, 20University of California San Diego, La Jolla, CA, 21University of Rochester Medical Center, Rochester, NY, 22Broad Institute of MIT and Harvard, Melrose, MA, 23Broad Institute of MIT and Harvard, Cambridge, MA, 24Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, 25NYU Grossman School of Medicine, New York, NY, 26Multiple, Bethesda, MD

    Background/Purpose: The G1 and G2 risk variants (RVs) in Apolipoprotein L1 (APOL1) associate with CKD and may contribute to poorer outcomes for African American (AA)…
  • Abstract Number: 0784 • ACR Convergence 2023

    Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial

    Brad Rovin1, Jorge Ross Terres2, Sophia Giang3, Thomas Schindler4, Armando Turchetta5, Jay Garg2, Richard Furie6, William F. Pendergraft III2 and Ana Malvar7, 1Ohio State University, Columbus, OH, 2Genentech, Inc., South San Francisco, CA, 3Genentech, Inc., San Francisco, CA, 4F. Hoffmann-La Roche Ltd, Basle, Switzerland, 5F. Hoffmann-La Roche Ltd, Basel, Switzerland, 6Northwell Health, Manhasset, NY, 7Hospital Fernandez, Buenos Aires, Argentina

    Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…
  • Abstract Number: 1998 • ACR Convergence 2023

    How to Tailor Osteoporosis Therapies in Patients with Advanced Liver Disease? Variations of Renal Function by Creatinine and Cystatin C

    Cristina Rodríguez-Alvear1, Mª Carmen López-González2, Elisabet Perea-Martínez3, Antonio Avilés-Hernández3, Eduardo Garín Cascales3, Nuria Buendía Sánchez3, Irene Calabuig-Sais1, Pilar Bernabeu-Gonzálvez3, Agustín Martínez-Sanchís1, Joaquim Esteve-Vives3, PALOMA VELA4, Cayetano Miralles Maciá3, Vega Jovani5 and Mariano Andrés1, 1Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, 2General University Hospital Dr. Balmis, Alacante, Spain, 3General University Hospital Dr. Balmis, Alicante, Spain, 4Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, 5Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain

    Background/Purpose: Rapid bone loss and increased fractures have been described after liver transplantation. Bisphosphonates are restricted in patients with significant kidney disease, as the drugs…
  • Abstract Number: 0855 • ACR Convergence 2023

    Real-world Experience with Avacopan in ANCA Vasculitis: A Multi-center Retrospective Cohort Analysis

    Sebastian Sattui1, Colin Diffie2, Aisha Shaikh3, Julia Ford4, David Bulbin5, Ora Gewurz-Singer6, Faten Aqeel7, Reza Zonozi8, Abdallah Sassine Geara9, Dustin Le7, Gabriel Sauvage8, Madeline Chung10, Isabelle Ayoub10, Frank Cortazar11, Andrew Bomback12, Karina Guaman12, Jason George13, John Niles8 and Duvuru Geetha7, 1University of Pittsburgh, Pittsburgh, PA, 2Washington University, St. Louis, MO, 3Washington University in St. Louis, St. Louis, MO, 4University of Michigan, Ann Arbor, MI, 5Geisinger Health System, Danville, PA, 6University of Michigan, Huntington Woods, MI, 7Johns Hopkins University, Baltimore, MD, 8Massachusetts General Hospital, Boston, MA, 9University of Pennsylvania, Philadelphia, PA, 10Ohio State University, Columbus, OH, 11New York Nephrology, Watervliet, NY, 12Columbia University, New York, NY, 13Geisenger Health, Danville, PA

    Background/Purpose: Avacopan (AVP) is a recently approved adjunct therapy for remission induction of ANCA-associated vasculitis (AAV). Data on real-world use of AVP in AAV are…
  • Abstract Number: 2114 • ACR Convergence 2023

    The Relationship Between Disease Activity of Rheumatoid Arthritis and Kidney Function

    Sho Fukui1, Wolfgang Winkelmayer2, Sara Tedeschi1, Javier Marrugo1, Hongshu Guan1, Leslie Harrold3, Heather Litman3, Tomohiro Shinozaki4 and Daniel Solomon5, 1Brigham and Women's Hospital, Boston, MA, 2Baylor College of Medicine, Houston, TX, 3CorEvitas, LLC, Waltham, MA, 4Tokyo University of Science, Tokyo, Japan, 5Brigham and Women's Hospital, Newton, MA

    Background/Purpose: Chronic kidney disease (CKD) is a common comorbidity of rheumatoid arthritis (RA) affecting 10-20% of patients. However, the influence of the longitudinal RA disease…
  • Abstract Number: 0857 • ACR Convergence 2023

    Change in Albuminuria in Patients with ANCA-Associated Vasculitis Treated with Avacopan

    Duvuru Geetha1, Frank Cortazar2, alexandre Karras3, Annette Bruchfeld4, Huibin Yue5, Peter Merkel6 and David Jayne7, 1Johns Hopkins University, Baltimore, MD, 2New York Nephrology, Watervliet, NY, 3HEGP - APHP, Paris, France, 4Karolinska Institutet, Stockholm, Sweden, 5Amgen, Inc., Thousand Oaks, CA, 6University of Pennsylvania, Philadelphia, PA, 7University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Urinary albumin:creatinine ratio (UACR) is an important biomarker of active glomerulonephritis, a common complication of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). In most glomerular…
  • Abstract Number: 2289 • ACR Convergence 2023

    Short and Long Term Outcomes of Patients with Pure Membranous Lupus Nephritis Compared to Patients with Proliferative Disease

    Fadi Kharouf1, Juan Pablo Diaz Martinez2, Dafna Gladman3 and Zahi Touma4, 1University Health Network and University of Toronto, Toronto, ON, Canada, 2Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, 3Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, 4University of Toronto, Toronto, ON, Canada

    b>Background/Purpose: Patients with pure membranous lupus nephritis (LN) are known to have a different disease course than those with proliferative disease. The aim of this…
  • Abstract Number: 0930 • ACR Convergence 2023

    Genetic Risk Profiles of Patients with Lupus Nephritis to Identify Those at Risk for Kidney Deterioration and Eventual Damage

    Aastha Khatiwada1, bethany wolf2, Isabelle Ayoub3, Juan Mejia-Vilet4, Ana Malvar5, Carl Langefeld6, Brad Rovin3, Jim Oates2 and Betty Tsao2, 1National Jewish Health, Denver, CO, 2Medical University of South Carolina, Charleston, SC, 3Ohio State University, Columbus, OH, 4Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 5Hospital Fernandez, Buenos Aires, Argentina, 6Wake Forest University School of Medicine, Winston-Salem, NC

    Background/Purpose: Many genetic variants are associated with lupus nephritis (LN). Yet, the majority of associated variants have a small effect size; hence, they convey small…
  • Abstract Number: 2336 • ACR Convergence 2023

    Identification of Urine Metabolites Linked to Disease Activity That Are Modulated by Anifrolumab in a Phase 2 LN Trial Using Untargeted Metabolomics Analysis

    David Jayne1, Eduardo Mysler2, Zahir Amoura3, Patrick Gavin4, Erik Allman4, Cristina Di Poto4, Xiang Tian4, Sonja Hess4, Eszter Csomor5, Philip Brohawn4, Daniel Muthas5, Adam Platt6, Hussein Al-Mossawi6, Catharina Lindholm5 and Nicola Ferrari6, 1University of Cambridge, Cambridge, United Kingdom, 2Organizacion Medica de Investigacion, Buenos Aires, Argentina, 3French National Reference Center for SLE, Hôpital La Pitié-Salpêtrière, Paris, France, 4BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 5BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 6BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: LN is a severe complication of SLE, affecting 21%–48% of patients.1 Development of noninvasive diagnostic tests for LN is ongoing; urinary biomarkers have good…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology